Risk factors for serious prescription opioid-related toxicity or overdose among veterans health administration patients

Pain Medicine (United States)

Volumn 15, Issue 11, 2014, Pages 1911-1929

  Zedler, Barbara ^a   Xie, Lin ^b   Wang, Li ^b   Joyce, Andrew ^a   Vick, Catherine ^a   Kariburyo, Furaha ^b   Rajan, Pradeep ^a   Baser, Onur ^b   Murrelle, Lenn ^a  

^a Venebio   (United States)

^b STATINMED RESEARCH   (United States)

Author keywords

Opioid; Overdose; Predictors; Prescription; Risk; Toxicity

Indexed keywords

CODEINE; FENTANYL; FENTANYL CITRATE; HYDROCODONE; HYDROMORPHONE; METHADONE; MORPHINE; MORPHINE SULFATE; OPIATE; OXYCODONE; OXYMORPHONE; PETHIDINE; TRAMADOL; NARCOTIC ANALGESIC AGENT; PRESCRIPTION DRUG;

ADULT; AGED; ARTICLE; BODY MASS; CASE CONTROL STUDY; CENTRAL NERVOUS SYSTEM DEPRESSION; CONTROLLED STUDY; DRUG CLEARANCE; DRUG INTOXICATION; DRUG MEGADOSE; DRUG OVERDOSE; FEMALE; GROUPS BY AGE; HEALTH CARE MANAGEMENT; HEALTH CARE UTILIZATION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MARRIAGE; MEDICAL HISTORY; OPIATE ADDICTION; PHARMACY; PRESCRIPTION; RESPIRATION DEPRESSION; RETROSPECTIVE STUDY; RISK FACTOR; VETERAN; VETERANS HEALTH; ADOLESCENT; MIDDLE AGED; PUBLIC HOSPITAL; UNITED STATES; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANALGESICS, OPIOID; CASE-CONTROL STUDIES; DRUG OVERDOSE; FEMALE; HOSPITALS, VETERANS; HUMANS; MALE; MIDDLE AGED; PRESCRIPTION DRUGS; RETROSPECTIVE STUDIES; RISK FACTORS; UNITED STATES; VETERANS; VETERANS HEALTH; YOUNG ADULT;

EID: 84911991239     PISSN: 15262375     EISSN: 15264637     Source Type: Journal    
DOI: 10.1111/pme.12480     Document Type: Article

References (80)

1. Jones CM, Mack KA, Paulozzi LJ. Pharmaceutical overdose deaths, United States, 2010. JAMA 2013;309(7):657-659.
2. Centers for Disease Control and Prevention. Vital signs: Overdoses of prescription opioid pain relievers-United States, 1999-2008. MMWR Morb Mortal Wkly Rep 2011;60(43):1487-1492.
3. SAMHSA Opioid Overdose Prevention Toolkit: Information for Prescribers. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2013. HHS Publication No. (SMA) 13-4742.
4. Jungquist CR, Karan S, Perlis ML. Risk factors for opioid-induced excessive respiratory depression. Pain Manag Nurs 2011;12(3):180-187.
5. Stephens E, Louden M, VanDe Voort J, etal. Opioid Toxicity: Medscape. 2012. Available at: http://emedicine.medscape.com/article/815784-overview (accessed December 2013); updated October 23, 2012, accessed December 8 2013.
6. Boudreau D, Von Korff M, Rutter CM, etal. Trends in long-term opioid therapy for chronic non-cancer pain. Pharmacoepidemiol Drug Saf 2009;18(12):1166-1175.
7. CDC Grand Rounds. Prescription Drug Overdoses-A US Epidemic. MMWR Morb Mortal Wkly Rep 2012;61(1):10-13.
8. Manchikanti L, Fellows B, Ailinani H, Pampati V. Therapeutic use, abuse, and nonmedical use of opioids: A ten-year perspective. Pain Physician 2010;13(5):401-435.
9. Parsells Kelly J, Cook SF, Kaufman DW, etal. Prevalence and characteristics of opioid use in the US adult population. Pain 2008;138(3):507-513.
10. Sullivan MD, Edlund MJ, Fan MY, etal. Trends in use of opioids for non-cancer pain conditions 2000-2005 in commercial and Medicaid insurance plans: The TROUP study. Pain 2008;138(2):440-449.
11. Sullivan MD, Edlund MJ, Steffick D, Unutzer J. Regular use of prescribed opioids: Association with common psychiatric disorders. Pain 2005;119(1-3):95-103.
12. Warner M, Chen LH, Makuc DM, Anderson RN, Minino AM. Drug poisoning deaths in the United States, 1980-2008. NCHS Data Brief 2011;(81):1-8.
13. Paulozzi LJ, Kilbourne EM, Shah NG, etal. A history of being prescribed controlled substances and risk of drug overdose death. Pain Med 2012;13(1):87-95.
14. American Academy of Pain Medicine and the American Pain Society. The use of opioids for the treatment of chronic pain. A consensus statement from the American Academy of Pain Medicine and the American Pain Society. Clin J Pain 1997;13:6-8.
15. Centers for Disease Control and Prevention. Vital Signs. Overdoses of prescription opioid pain relievers and other drugs among women-United States, 1999-2010. Morb Mortal Wkly Rep 2013;62(26):537-542.
16. Lanier WA, Johnson EM, Rolfs RT, Friedrichs MD, Grey TC. Risk factors for prescription opioid-related death, Utah, 2008-2009. Pain Med 2012;13(12):1580-1589.
17. Madadi P, Hildebrandt D, Lauwers AE, Koren G. Characteristics of opioid-users whose death was related to opioid-toxicity: a population-based study in Ontario, Canada. PLoS One. 2013;8(4):e60600.
18. Paulozzi LJ, Logan JE, Hall AJ, etal. A comparison of drug overdose deaths involving methadone and other opioid analgesics in West Virginia. Addiction 2009;104(9):1541-1548.
19. Wunsch MJ, Nakamoto K, Behonick G, Massello W. Opioid deaths in rural Virginia: A description of the high prevalence of accidental fatalities involving prescribed medications. Am J Addict 2009;18(1):5-14.
20. Hall AJ, Logan JE, Toblin RL, etal. Patterns of abuse among unintentional pharmaceutical overdose fatalities. JAMA 2008;300(22):2613-2620.
21. Bohnert AS, Valenstein M, Bair MJ, etal. Association between opioid prescribing patterns and opioid overdose-related deaths. JAMA 2011;305(13):1315-1321.
22. Substance Abuse and Mental Health Services Administration. Results from the 2009 National Survey on Drug Use and Health: volume 1: summary of national findings. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2010.
23. Coolen P, Best S. Overdose Deaths Involving Prescription Opioids Among Medicaid Enrollees-Washington, 2004-2007. Atlanta, Ga: Centers for Disease Control and Prevention, 2009 Contract No.: 42.
24. McDonald DC, Carlson K, Izrael D. Geographic variation in opioid prescribing in the U.S. J Pain 2012;13(10):988-996.
25. Dunn KM, Saunders KW, Rutter CM, etal. Opioid prescriptions for chronic pain and overdose: A cohort study. Ann Intern Med 2010;152(2):85-92.
26. Joint Commission on Accreditation of Health Care Organizations. Safe use of opioids in hospitals: Joint Commission on Accreditation of Health Care Organizations. 2012. Available at: http://www.jointcommission.org/assets/1/18/SEA_49_opioids_8_2_12_final.pdf (accessed December 2013).
27. Webster LR, Cochella S, Dasgupta N, etal. An analysis of the root causes for opioid-related overdose deaths in the United States. Pain Med 2011;12(suppl 2):S26-35.
28. Nuckols TK, Anderson L, Popescu I, etal. Opioid prescribing: A systematic review and critical appraisal of guidelines for chronic pain. Ann Intern Med 2013;160(1):38-47.
29. Braden JB, Russo J, Fan MY, etal. Emergency department visits among recipients of chronic opioid therapy. Arch Intern Med 2010;170(16):1425-1432.
30. Morasco BJ, Duckart JP, Carr TP, Deyo RA, Dobscha SK. Clinical characteristics of veterans prescribed high doses of opioid medications for chronic non-cancer pain. Pain 2010;151(3):625-632.
31. Centers for Disease Control and Prevention. ICD-9-CM Official Guidelines for Coding and Reporting: Centers for Disease Control and Prevention. Available at: http://www.cdc.gov/nchs/data/icd9/icd9cm_guidelines_2011.pdf (accessed November 2013).
32. Charlson ME, Charlson RE, Peterson JC, etal. The Charlson comorbidity index is adapted to predict costs of chronic disease in primary care patients. J Clin Epidemiol 2008;61(12):1234-1240.
33. Baser O, Xie L, Mardekian J, etal. Prevalence of Diagnosed Opioid Abuse and its Economic Burden in the Veterans Health Administration. Pain Pract 2013.
34. Fleming MF, Balousek SL, Klessig CL, Mundt MP, Brown DD. Substance use disorders in a primary care sample receiving daily opioid therapy. J Pain 2007;8(7):573-582.
35. Walker JM, Farney RJ, Rhondeau SM, etal. Chronic opioid use is a risk factor for the development of central sleep apnea and ataxic breathing. J Clin Sleep Med 2007;3(5):455-461.
36. Xie L, Joshi AV, Schaaf D, etal. Differences in Healthcare Utilization and Associated Costs Between Patients Prescribed vs. Nonprescribed Opioids During an Inpatient or Emergency Department Visit. Pain Pract 2013.
37. Von Korff M, Saunders K, Ray GT, Boudreau D, Campbell D, Merrill J, etal. Defacto long-term opioid therapy for non-cancer pain. Clin J Pain 2008;24(6):521-527.
38. Vieweg WV, Lipps WF, Fernandez A. Opioids and methadone equivalents for clinicians. Prim Care Companion J Clin Psychiatry 2005;7(3):86-88.
39. Miaskowski C, Bair M, Chou R, D'Arcy Y, Hartwick C, Huffman L, etal., Principles of Analgesic Use in the Treatment of Acute Pain and Cancer Pain. Sixth ed. Glenview, IL: American Pain Society; 2008. p. 19-38.
40. Fine PG, Portenoy RK. A Clinical Guide to Opioid Analgesia. Minneapolis: McGraw Hill; 2004.
41. Technical Assistance Guide No. 01-13: Calculating Daily Morphine Milligram Equivalents: Prescription Drug Monitoring Program Training and Technical Assistance Center. 2013. Available at: http://www.pdmpassist.org/pdf/BJA_performance:measure_aid_MME_conversion.pdf (accessed March 2014). updated Feb 28 2013.
42. Prescription Drug Monitoring Program Training and Technical Assistance Center. Technical Assistance Guide No. 02-13: Daily Morphine Milligram Equivalents Calculator and Guide.: Prescription Drug Monitoring Program Training and Technical Assistance Center. 2013. Available at: http://www.pdmpassist.org/pdf/bja_performance:measure_aid_mme_conversion_tool.pdf (accessed March 2014). updated May 1 2013.
43. Cook NR. Use and misuse of the receiver operating characteristic curve in risk prediction. Circulation 2007;115(7):928-935.
44. SAS. 9.3. SAS Institute. Cary, NC. 2013.
45. Cerda M, Ransome Y, Keyes KM, etal. Prescription opioid mortality trends in New York City, 1990-2006: Examining the emergence of an epidemic. Drug Alcohol Depend 2013;132(1-2):53-62.
46. Johnson EM, Lanier WA, Merrill RM, etal. Unintentional prescription opioid-related overdose deaths: Description of decedents by next of kin or best contact, Utah, 2008-2009. J Gen Intern Med 2013;28(4):522-529.
47. Johnson JA. Ethnic differences in cardiovascular drug response: Potential contribution of pharmacogenetics. Circulation 2008;118(13):1383-1393.
48. Joung IM, van de Mheen H, Stronks K, van Poppel FW, Mackenbach JP. Differences in self-reported morbidity by marital status and by living arrangement. Int J Epidemiol 1994;23(1):91-97.
49. Joung IM, van der Meer JB, Mackenbach JP. Marital status and health care utilization. Int J Epidemiol 1995;24(3):569-575.
50. Mor A, Ulrichsen SP, Svensson E, Berencsi K, Thomsen RW. Does marriage protect against hospitalization with pneumonia? A population-based case-control study. Clin Epidemiol 2013;5:397-405.
51. Aizer AA, Chen MH, McCarthy EP, etal. Marital status and survival in patients with cancer. J Clin Oncol 2013;31(31):3869-3876.
52. Sammon JD, Morgan M, Djahangirian O, etal. Marital status: A gender-independent risk factor for poorer survival after radical cystectomy. BJU Int 2012;110(9):1301-1309.
53. National Institute on Drug Abuse. Prescription Drugs: Abuse and Addiction. Older Adults. Available at: www.drugabuse.gov/publications/research-reports/prescription-drugs/trends-in-prescription-drug-abuse/older-adults (accessed October 2013).
54. American Geriatrics Society Panel on Pharmacological Management of Persistent Pain in Older P. Pharmacological management of persistent pain in older persons. J Am Geriatr Soc 2009;57(8):1331-1346.
55. Chou R, Fanciullo GJ, Fine PG, etal. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain 2009;10(2):113-130.
56. Edlund MJ, Sullivan M, Steffick D, Harris KM, Wells KB. Do users of regularly prescribed opioids have higher rates of substance use problems than nonusers? Pain Med 2007;8(8):647-656.
57. Seal KH, Shi Y, Cohen G, etal. Association of mental health disorders with prescription opioids and high-risk opioid use in US veterans of Iraq and Afghanistan. JAMA 2012;307(9):940-947.
58. Food and Drug Administration. FDA Blueprint for Prescriber Education for Extended-Release and Long-Acting Opioid Analgesics. US Food and Drug Administration. 2013.
59. Centers for Disease Control and Prevention. Vital Signs: Risk for overdose from methadone used for pain relief-United States, 1999-2010. MMWR Morb Mortal Wkly Rep 2012;61(26):493-497.
60. Gomes T, Juurlink DN, Dhalla IA, etal. Trends in opioid use and dosing among socio-economically disadvantaged patients. Open Med 2011;5(1):e13-22.
61. Fine PG, Portenoy RK, Ad Hoc Expert Panel on Evidence R, Guidelines for Opioid R. Establishing "best practices" for opioid rotation: Conclusions of an expert panel. J Pain Symptom Manage 2009;38(3):418-425.
62. McNicol E. Opioid equianalgesic conversions. J Pain Palliat Care Pharmacother 2009;23(4):459.
63. Shaheen PE, Walsh D, Lasheen W, Davis MP, Lagman RL. Opioid equianalgesic tables: Are they all equally dangerous? J Pain Symptom Manage 2009;38(3):409-417.
64. Webster LR, Fine PG. Review and critique of opioid rotation practices and associated risks of toxicity. Pain Med 2012;13(4):562-570.
65. Kalvass JC, Olson ER, Cassidy MP, Selley DE, Pollack GM. Pharmacokinetics and pharmacodynamics of seven opioids in P-glycoprotein-competent mice: Assessment of unbound brain EC50, u and correlation of in vitro, preclinical, and clinical data. J Pharmacol Exp Ther 2007;323(1):346-355.
66. Liang DY, Liao G, Lighthall GK, Peltz G, Clark DJ. Genetic variants of the P-glycoprotein gene Abcb1b modulate opioid-induced hyperalgesia, tolerance and dependence. Pharmacogenet Genomics 2006;16(11):825-835.
67. Pereira J, Lawlor P, Vigano A, Dorgan M, Bruera E. Equianalgesic dose ratios for opioids. a critical review and proposals for long-term dosing. J Pain Symptom Manage 2001;22(2):672-687.
68. US Veterans' Health Affairs Administration. Veterans Administration/Department of Defense Clinical Practice Guideline for Management of Opioid Therapy for Chronic Pain. 2010. Available at: http://www.va.gov/painmanagement/docs/cpg_opioidtherapy_fulltext.pdf (accessed March 2014).
69. Leppert W, Luczak J. The role of tramadol in cancer pain treatment-A review. Support Care Cancer 2005;13(1):5-17.
70. Drug Enforcement Administration. Tramadol, Drug and Chemical Evaluation. US Drug Enforcement Administration, Office of Diversion Control. August 29 2013. Available at: http://www.deadiversion.usdoj.gov/drug_chem_info/tramadol.pdf (accessed March 2014).
71. Tramadol Label. Daily Med: Current Medication Information. National Library of Medicine. Available at: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=45f59e6f-1794-40a4-8f8b-3a9415924468 (accessed March 2014).
72. Institute of Medicine. Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research. Washington, DC: The National Academies Press; 2011.
73. Inocencio TJ, Carroll NV, Read EJ, Holdford DA. The economic burden of opioid-related poisoning in the United States. Pain Med 2013;14(10):1534-1547.
74. Albert S, Brason FW, Sanford CK, etal. Project Lazarus: Community-based overdose prevention in rural North Carolina. Pain Med 2011;12(suppl 2):S77-85.
75. Furlan AD, Reardon R, Weppler C. Opioids for chronic noncancer pain: A new Canadian practice guideline. CMAJ 2010;182(9):923-930.
76. Passik SD, Kirsh KL, Casper D. Addiction-related assessment tools and pain management: Instruments for Screening, treatment planning, and monitoring compliance. Pain Med 2008;9:S145-166.
77. Beletsky L, Rich JD, Walley AY. Prevention of fatal opioid overdose. JAMA 2012;308(18):1863-1864.
78. Wheeler E, Davidson PJ, Jones TS, Irwin KS. Community-Based Opioid Overdose Prevention Programs Providing Naloxone-United States, 2010. Atlanta, Ga: Centers for Disease Control and Prevention; 2012.
79. Kim D, Irwin KS, Khoshnood K. Expanded access to naloxone: Options for critical response to the epidemic of opioid overdose mortality. Am J Public Health 2009;99(3):402-407.
80. American Medical Association. AMA Adopts New Policies at Annual Meeting: American Medical Association. 2012. Available at: https://www.ama-assn.org/ama/pub/news/news/2012-06-19-ama-adopts-new-policies.page (accessed December 2013).